Results 71 to 80 of about 1,870 (108)

570. Intravenous Phase I Clinical Proof-of-Concept Trial with JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Refractory Metastatic Cancers

Molecular Therapy, 2009
openaire   +1 more source

Vaccinia Virus-A Swiss Army Knife Against Cancer. [PDF]

Cancers (Basel)
Stawowczyk M, Ye Y, Chen NG.
europepmc   +1 more source

Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform. [PDF]

Front Immunol
Li L, Chen Z, Yan Y, Zhang L.
europepmc   +1 more source

33. Demonstration of Delivery and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following a Single Intravenous Infusion in Patients with Refractory Metastatic Cancers

Molecular Therapy, 2010
openaire   +1 more source

The fall of the genome protectors triad: PBRM1, SETD2, and BAP1's impact on metabolism and immunity in clear cell renal cell carcinoma. [PDF]

Front Cell Dev Biol
Johnson M, Turcotte S.
europepmc   +1 more source

Cancer genetics and response to oncolytic virus treatment for ovarian cancer. [PDF]

Pharmacogenomics
Fletcher EL, Cudmore AO, Vanderhyden BC.
europepmc   +1 more source

Translation of oncolytic viruses in sarcoma. [PDF]

Mol Ther Oncol
Robinson SI, Rochell RE, Penza V, Naik S.   +3 more
europepmc   +1 more source

Recent progress in combination therapy of oncolytic vaccinia virus. [PDF]

Front Immunol
Mirbahari SN, Da Silva M, Zúñiga AIM, Kooshki Zamani N, St-Laurent G, Totonchi M, Azad T.   +6 more
europepmc   +1 more source

Mechanisms of Oncolytic Virus-Induced Multi-Modal Cell Death and Therapeutic Prospects. [PDF]

Int J Mol Sci
Xu J, Liu C, An Y, Sun J, Wang S, Xia Q.
europepmc   +1 more source

Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape. [PDF]

World J Gastrointest Oncol
Xiao R, Jin H, Huang F, Huang B, Wang H, Wang YG.   +5 more
europepmc   +1 more source